JP5775300B2 - カンナビノイド含有植物抽出物の新規な用途 - Google Patents

カンナビノイド含有植物抽出物の新規な用途 Download PDF

Info

Publication number
JP5775300B2
JP5775300B2 JP2010503587A JP2010503587A JP5775300B2 JP 5775300 B2 JP5775300 B2 JP 5775300B2 JP 2010503587 A JP2010503587 A JP 2010503587A JP 2010503587 A JP2010503587 A JP 2010503587A JP 5775300 B2 JP5775300 B2 JP 5775300B2
Authority
JP
Japan
Prior art keywords
cannabinoid
cannabinoids
channel
trpa1
channels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010503587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524912A5 (enExample
JP2010524912A (ja
Inventor
ヴィンチェンツォ・ディ・マルツォ
ルチャーノ・デ・ペトロチェリス
アニエッロ・スキアーノ・モリエッロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of JP2010524912A publication Critical patent/JP2010524912A/ja
Publication of JP2010524912A5 publication Critical patent/JP2010524912A5/ja
Application granted granted Critical
Publication of JP5775300B2 publication Critical patent/JP5775300B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
JP2010503587A 2007-04-19 2008-04-17 カンナビノイド含有植物抽出物の新規な用途 Active JP5775300B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0707610.2 2007-04-19
GB0707610A GB2448535A (en) 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts
PCT/GB2008/001359 WO2008129258A1 (en) 2007-04-19 2008-04-17 New use for cannabinoid-containing plant extracts

Publications (3)

Publication Number Publication Date
JP2010524912A JP2010524912A (ja) 2010-07-22
JP2010524912A5 JP2010524912A5 (enExample) 2011-03-10
JP5775300B2 true JP5775300B2 (ja) 2015-09-09

Family

ID=38135105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503587A Active JP5775300B2 (ja) 2007-04-19 2008-04-17 カンナビノイド含有植物抽出物の新規な用途

Country Status (8)

Country Link
US (1) US20100249223A1 (enExample)
EP (1) EP2146731B1 (enExample)
JP (1) JP5775300B2 (enExample)
CN (1) CN101678059A (enExample)
CA (1) CA2684562A1 (enExample)
ES (1) ES2717839T3 (enExample)
GB (1) GB2448535A (enExample)
WO (1) WO2008129258A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
KR101063352B1 (ko) 2008-11-28 2011-09-07 고려대학교 산학협력단 Ｔｒｐａ１ 활성 억제 약물 및 이의 활용
DE102010002558A1 (de) 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
JP6061448B2 (ja) * 2011-03-10 2017-01-18 株式会社マンダム 被験物質の評価方法
KR20120111125A (ko) * 2011-03-31 2012-10-10 주식회사한국전통의학연구소 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
GB2524689B (en) 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US9776014B2 (en) 2012-05-03 2017-10-03 Magdent Ltd. Bone enhancement device and method
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
JP6673895B2 (ja) 2014-03-21 2020-03-25 エスティー アンド ティー インターナショナル，インコーポレイティド アサ属抽出方法及び組成物
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
CN105477635A (zh) * 2014-09-15 2016-04-13 中国人民解放军第二军医大学 一种治疗持续性慢性疼痛的靶点和药物
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
BR122021018502B1 (pt) 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
WO2016123475A1 (en) 2015-01-31 2016-08-04 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
MX2017010872A (es) 2015-02-27 2018-05-07 Ebbu Llc Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2017013661A1 (en) 2015-07-22 2017-01-26 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
WO2017059088A1 (en) * 2015-09-30 2017-04-06 George Edward Hoag Topical analgesic pain relife formulations, manufacture and methods of use thereof
WO2017091764A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3471745B1 (en) * 2016-06-15 2025-03-26 Ojai Energetics PBC Compositions for reducing oxidative stress
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
CN110177543A (zh) 2016-08-29 2019-08-27 凯诺比生长公司 包含纯化大麻素的水溶性组合物
IL265902B2 (en) * 2016-10-11 2024-04-01 Gbs Global Biopharma Inc Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
IL269158B2 (en) 2017-03-05 2024-04-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Cannabis compositions enriched in thca and their use in treating inflammatory diseases
AU2018273194B2 (en) 2017-05-22 2023-05-25 Gbs Global Biopharma, Inc. Myrcene- and cannabinoid-containing compositions which target TRPV1
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
EP3675809B1 (de) 2017-08-31 2023-09-27 Basf Se Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CN109939014A (zh) * 2017-12-20 2019-06-28 汉义生物科技（北京）有限公司 一种含有大麻素的口气清新剂
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
JP2021521277A (ja) 2018-04-09 2021-08-26 エレヴェット・サイエンシズ 動物における疼痛の処置のためのアサ抽出物
WO2019222459A1 (en) * 2018-05-18 2019-11-21 Diverse Biotech, Inc. Cannabinoid preparations and therapeutic uses
JP2021524465A (ja) * 2018-05-22 2021-09-13 ジービーエス グローバル バイオファーマ，インコーポレイテッド Ｔｒｐｖ１モジュレーションに使用するためのカンナビノイド及び／又はテルペン
CA3104795A1 (en) * 2018-06-28 2020-01-02 Canopy Growth Corporation Compositions and methods for agonizing the cb2 receptor
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
EP3968970A4 (en) * 2019-05-16 2023-01-25 Buzzelet Development And Technologies Ltd Local anesthetic comprising a trp channel modulator
WO2021055079A1 (en) 2019-09-16 2021-03-25 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
CN112569220B (zh) * 2019-09-30 2023-03-07 云南汉盟制药有限公司 四氢次大麻酚在制备用于治疗肺动脉高压药物中的应用及含有四氢次大麻酚的药物组合物
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US20210100737A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021070120A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021188983A1 (en) * 2020-03-20 2021-09-23 The Queen's Medical Center Cannabinoid compositions
IL297546A (en) * 2020-04-24 2022-12-01 Zyus Life Sciences Inc Cannabichromene formulation for pain management
KR102433007B1 (ko) * 2020-07-28 2022-08-16 동의대학교 산학협력단 산골취 추출물을 포함하는 신경병증성 통증 예방 및 개선용 조성물
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
CN119912407A (zh) * 2023-10-31 2025-05-02 北京红惠新医药科技有限公司 大麻二酚环氧化物的制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) * 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
JPH0426622A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 制癌剤
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US6403126B1 (en) * 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
EP1497328A2 (en) * 2002-04-16 2005-01-19 Bayer HealthCare AG Regulation of human transient receptor potential channel
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
JP2009513159A (ja) * 2005-10-31 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ２のモジュレーターを同定するための組成物および方法
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain

Also Published As

Publication number Publication date
GB2448535A (en) 2008-10-22
ES2717839T3 (es) 2019-06-25
EP2146731A1 (en) 2010-01-27
GB0707610D0 (en) 2007-05-30
EP2146731B1 (en) 2019-01-16
CN101678059A (zh) 2010-03-24
CA2684562A1 (en) 2008-10-30
JP2010524912A (ja) 2010-07-22
US20100249223A1 (en) 2010-09-30
WO2008129258A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
JP5775300B2 (ja) カンナビノイド含有植物抽出物の新規な用途
Dai et al. Celastrol inhibits microglial pyroptosis and attenuates inflammatory reaction in acute spinal cord injury rats
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
WO2009093018A1 (en) New use for cannabinoids
ZA200610242B (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
JP2019537628A (ja) 併用療法
WO2019130215A1 (en) Cannabis compositions for the treatment of inflammatory skin disorders
Ansari et al. Nigella sativa: A non-conventional herbal option for the management of seasonal allergic rhinitis
Peng et al. Rolipram attenuates early brain injury following experimental subarachnoid hemorrhage in rats: possibly via regulating the SIRT1/NF-κB pathway
Ye et al. Protective effect of n-butyl alcohol extracts from Rhizoma Pinelliae Pedatisectae against cerebral ischemia-reperfusion injury in rats
Weng et al. Macranthol attenuates lipopolysaccharide-induced depressive-like behaviors by inhibiting neuroinflammation in prefrontal cortex
WO2001041751A2 (en) Phytoestrogens for treating als
Saleh et al. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors
Paland et al. Cannabis and rheumatoid arthritis: A scoping review evaluating the benefits, risks, and future research directions
Peng et al. Neuroprotective effects of magnesium lithospermate B against subarachnoid hemorrhage in rats
TWI776234B (zh) 藥學組合物及其於治療肌少症之用途
EP4601630A1 (en) Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity
JP2022519873A (ja) カンナビノイド受容体アゴニスト及びセリンヒドロラーゼ酵素阻害剤ベースの抗不安治療製品
HK1139877A (en) Cannabinoid-containing plant extracts for the treatment of prostate cancer
HK1139877B (en) Cannabinoid-containing plant extracts for the treatment of prostate cancer
Li et al. Quercetin regulates depression-like behavior in CUMS rat models via TLR4/NF-κB signaling
Yu et al. α-Cyperone safeguards against cerebral ischaemia‒reperfusion injury through the activation of the Nrf2 signalling pathway.
Ross The analgesic effects of cannabis
Zhao et al. Protective effect of Ginsenoside Rc on the complete Freund’s adjuvant-induced rheumatoid arthritis in rats by attenuation of inflammatory mediators through inhibition NF-κB pathway
Cortez et al. Cannabis sativa–A matter of physical, mental, and social health

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130305

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150703

R150 Certificate of patent or registration of utility model

Ref document number: 5775300

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250